Table 3.
Cell line | Tumor type | Immune Attack | Library | Sensitivity/resistance | Publication | Organism |
---|---|---|---|---|---|---|
B16F10-OVA | Melanoma | OT-I CD8+ T cells | Brie | Resistance | Kearney et al.4 | Mus musculus |
Renca-HA | Renal adenocarcinoma | CL4 CD8+ T cells | Mouse Toronto Knockout | Both | Lawson et al.5 | Mus musculus |
EMT6-HA | Mammary carcinoma | CL4 CD8+ T cells | Mouse Toronto Knockout | Both | Lawson et al.5 | Mus musculus |
CT26-HA | Colon carcinoma | CL4 CD8+ T cells | Mouse Toronto Knockout | Both | Lawson et al.5 | Mus musculus |
4T1-HA | Mammary carcinoma | CL4 CD8+ T cells | Mouse Toronto Knockout | Both | Lawson et al.5 | Mus musculus |
MC38-OVA | Melanoma | OT-I CD8+ T cells | Mouse Toronto Knockout | Both | Lawson et al.5 | Mus musculus |
B16F10-OVA | Melanoma | OT-I CD8+ T cells | Mouse Toronto Knockout | Both | Lawson et al.5 | Mus musculus |
B16F10-OVA | Melanoma | OT-I CD8+ T cells | Brie | Both | Pan et al.7 | Mus musculus |
Mel624-NY-ESO+ | Melanoma | ESO CD8+ T cells | GeCKOv2 | Resistance | Patel et al.8 | Homo sapiens |
D10-MART-1+IFNGR1KO | Melanoma | MART-1 CD8+ T cells | GeCKOv2 | Both | Vredevoogd et al.9 | Homo sapiens |
OVA, ovalbumin.